Stem cell therapy: a novel treatment option for cerebral malaria? by Wei Wang et al.
Wang et al. Stem Cell Research & Therapy  (2015) 6:141 
DOI 10.1186/s13287-015-0138-6COMMENTARY Open AccessStem cell therapy: a novel treatment option
for cerebral malaria?
Wei Wang1*, Hui Qian2 and Jun Cao1*
See related research by Souza et al., http://www.stemcellres.com/content/6/1/102Abstract
Cerebral malaria, a severe form of the disease, is one
of the most severe complications of infection with
Plasmodium parasites and a leading cause of malaria
mortality. Currently available antimalarial therapy has
proven insufficient to prevent neurological complications
and death in all cases of cerebral malaria. Souza and
colleagues observed that transplantation of bone
marrow-derived mesenchymal stromal cells (BM-MSCs)
increased survival, reduced parasitemia, decreased
malaria pigment accumulation in the spleen, liver and
kidney, elevated Kupffer cell count in liver, alleviated
renal injury and lung inflammation, and improved lung
mechanics in an experimental mouse model of cerebral
malaria. Although plenty of challenges lie ahead, their
findings show the promise of BM-MSC therapy for the
treatment of cerebral malaria.stem cell therapy for malaria was firstly documented inAs one of the most severe complications of infection with
Plasmodium parasites, cerebral malaria may cause neuro-
logical disorders that manifest as severe headache, drowsi-
ness, confusion, coma, and convulsion, and affect other
vital organs such as lung, kidney, heart, spleen and liver.
Worldwide, cerebral malaria is a leading cause of malaria
mortality, responsible for almost 20 % of adult deaths and
15 % of childhood deaths. To date, there is no effective
and safe treatment available for cerebral malaria, notably
for use in children, who represent the majority of cases.
Even patients that are given standard antimalarial therapy
at an early phase still face a high risk of dying despite
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cognitive impairment. In a recent issue of Stem Cell
Research & Therapy, Souza and colleagues [1] observed
that administration of bone marrow-derived mesenchymal
stromal cells (BM-MSCs) increased survival and reduced
parasitemia and malaria pigment deposition in the spleen,
liver, kidney and lung in an experimental mouse model of
cerebral malaria. Their findings may provide a new option
for the treatment of cerebral malaria.
To date, stem cell therapy has shown satisfactory
outcomes in the treatment of a wide variety of human
diseases, mainly tissue injury and immune disorders
[2]. With the hope of conquering parasitic diseases,
stem cell therapy has been introduced for parasitic in-
fections since the 1990s [3], with the most successful
attempt seen in Chagas disease [4], an emerging global
health threat caused by the parasite Trypanosoma cruzi
that may cause fatal heart diseases [5]. The value of
1991, when Japanese scientists found that multipotent
hemopoietic stem cells contributed to host defense
against Plasmodium berghei infection, and increased
the survival of infected mice [6]. Subsequently, trans-
plantation of myeloid cells produced by interleukin 7
receptor-alpha (IL-7Rα)+ c-Kithi progenitors, which
were isolated from mice experimentally infected with P.
chabaudi, was found to result in clearance of infected
erythrocytes in infected mice, and promote recovery
from the infection [7]. The advantages of high self-
renewal ability, multilineage differentiation, wide pres-
ence, easy isolation and rapid expansion facilitate the
‘gold rush’ to use MSCs, and the number of clinical
trials on MSCs has been rising since 2004 [8]. As a con-
sequence, the in vivo efficacy of MSC treatment against
malaria was evaluated in a mouse model of P. berghei
infection; administration of MSCs was found to confer
host resistance against malaria through increasing IL-
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strate the promise of MSCs in the treatment of malaria;
however, no data are available on the effect of MSC
therapy on organs affected due to cerebral malaria.
The first insight from this study is that intravenous
injection of BM-MSCs results in reduced mortality and
parasitemia, decreased malaria pigment accumulation in
the spleen, liver and kidney, elevated Kupffer cell count
in liver, alleviated renal injury and lung inflammation,
and improved lung mechanics in mouse cerebral mal-
aria models experimentally infected with P. berghei.
Surprisingly, however, these alterations seem not be as-
sociated with changes in the expression of pro-
inflammatory cytokines, including interferon-gamma,
tumor necrosis factor alpha and chemokine (C-X-C
motif ) ligand 1 (CXCL1) as detected using enzyme-
linked immunosorbent assays 5 days post-infection, but
rather to reduced peripheral parasitemia. As stated in
the discussion, the duration of observation seems rela-
tively short. In the future, the time-course effect of
MSC therapy on Plasmodium infection should be eval-
uated over an extended period of time. Since multiple
cell tracking strategies have been developed to track
the migration, distribution and target tissues of intra-
venously injected stem cells [10], tracking of labeled
MSCs given to the animal models is required in future
studies.
Second, this study demonstrates that administration of
BM-MSCs results in elevated counts of astrocytes and
oligodendrocytes in P. berghei-infected mice, which impli-
cates tissue repair. Interestingly, assessment of brain injury
with a five-point, semi-quantitative, severity-based scoring
system revealed no significant difference in tissue inflam-
mation or severity of histoarchitectural damage between
the treated and untreated infected mice, indicating that
BM-MSC therapy does not affect the inflammatory
process of the brain tissues. In addition, BM-MSC therapy
was found to mitigate renal injury caused by P. berghei,
while it did not improve renal function, as reflected by no
significant difference in serum creatinine, blood urea
nitrogen, blood urea nitrogen/serum creatinine ratio or
urinary creatinine between the treated and untreated
groups. Further studies to investigate the exact mecha-
nisms underlying these differences seem justified.
However, the use of rodent malaria parasite for mod-
eling experimental cerebral malaria remains controver-
sial, since the major difference between human cerebral
malaria and the P. berghei ANKA models is thought to
be the extent of parasite sequestration in the brain [11].
Therefore, more evidence should be obtained from non-
human primate models prior to the consideration of
clinical trials of this new treatment option. Additionally,
the issue of safety related to BM-MSC therapy is not
addressed in this study.Conclusion
Souza and colleagues [1] evaluate, for the first time, the
effects of BM-MSC therapy in multiple organ dysfunc-
tion during experimental cerebral malaria, and demon-
strate that administration of BM-MSCs results in
reduced mortality and parasitemia. Although plenty of
challenges lie ahead, the results of this study validate
the promise of BM-MSC therapy in the treatment of
cerebral malaria. The ultimate goal of any intervention
is to improve clinical outcome and prognosis. Hence, al-
though the study by Souza and colleagues is a major ad-
vance towards the treatment of cerebral malaria, we still
need to devise optimal strategies to improve the control
of encephalopathy and other complications of cerebral
malaria.
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